Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Dry Eye Disease (DED) Clinical Trial

Official title:
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)

Status Completed

Clinical Trial Summary

This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03333057
Study type	Interventional
Source	Novaliq GmbH
Contact
Status	Completed
Phase	Phase 2
Start date	January 3, 2018
Completion date	July 27, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04140227` - Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)	Phase 3
Completed	`NCT04393441` - Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease	Phase 3
Completed	`NCT04036292` - Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease	Phase 3
Completed	`NCT04139798` - Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)	Phase 3
Completed	`NCT04523142` - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004	Phase 3
Completed	`NCT01998802` - Phase 3 Study of EBI-005 in Dry Eye Disease	Phase 3
Completed	`NCT05723770` - Effects of NOV03 on the Tear Film	Phase 4